Tushar Pandey: Hounoured to Be Part of Hematocon 2025
Tushar Pandey, Editorial Board Member at Journal of Cancer Chemotherapy, shared on LinkedIn:
”HONOURED TO BE PART OF HEMATOCON 2025
Grateful for the opportunity to represent HALDWANI, UTTARAKHAND and the RAGHAV INSTITUTE OF HEMATOLOGY, HEMATO-ONCOLOGY and BONE MARROW TRANSPLANT (RIHOB) as FACULTY at the National Hematology Conference — Hematocon 2025.
Participated in a deeply insightful session on “INFECTIONS IN BONE MARROW TRANSPLANT AND NEUTROPENIC SETTINGS AND THEIR MANAGEMENT,” an area that remains vital to improving outcomes and safety in hematology and transplant care.
It was a privilege to share thoughts and exchange ideas with distinguished HEMATOLOGISTS — DR. Faheema Hasan , DR. ADITYA JANDIAL, DR. POORVI KAPOOR, AND DR. SAYAN ROY.
The discussion brought forward valuable perspectives on managing complex infections in immunocompromised patients.
Looking forward to continuing our collective efforts to strengthen hematology and transplant services across UTTARAKHAND AND NORTH INDIA.
Committed to advancing excellence in Hematology, Oncology and BMT care.”
Stay updated with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator